Patents Assigned to Ibex Technologies R and D, Inc.
  • Patent number: 6093563
    Abstract: The present invention describes a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high resolution ion exchange chromatography and size exclusion is outlined. A 77,000.+-.5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000.+-.2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned and methods for their use are described.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: July 25, 2000
    Assignee: IBEX Technologies R and D, Inc.
    Inventors: D. Clark Bennett, Maryse Laliberte, Kangfu Gu, Joseph Zimmermann, Anna Lydia Tkalec, Dominique Fink, Robert Linhardt
  • Patent number: 6054569
    Abstract: The present invention describes a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high resolution ion exchange chromatography and size exclusion is outlined. A 77,000.+-.5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000.+-.2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned and methods for their use are described.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: April 25, 2000
    Assignee: IBEX Technologies R and D, Inc.
    Inventors: D. Clark Bennett, Maryse Laliberte, Kangfu Gu, Joseph Zimmermann, Anna Lydia Tkalec, Dominique Fink, Robert Linhardt
  • Patent number: 5997863
    Abstract: Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: December 7, 1999
    Assignee: Ibex Technologies R and D, Inc.
    Inventors: Joseph Zimmermann, Israel Vlodavsky, Clark Bennett, Pamela Danagher, Richard Broughton